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Comparison to Reference Epigenome
We utilized data from the recently released Human epigenome reference data [19] to annotate the set of deferentially methylated CpG sites. We mapped hyper and hypo DMPs in the promoter region from our data against two reference epigenome breast cell lines: HMEC(Human mammary primary epithelial cells), and vHMEC (Human mammary primary epithelial cell variant) [20, 21] ].We examined the change in chromatin statesfrom the 15-chromatin states model [19] -that accompany the acquisition or loss of DNA methylation in the context of transitioning from normal to tumor states. Our results revealed a noticeable gain of repressive marks for the hypermethylated DMPs, which increased from 55.5% in HMEC cells to 78.7% in vHMEC cells. Interestingly, we also found a slight increase in the percentage of repressive marks in the hypomethylated DMPs, which increased from 54.3% to 61.6%. Notably, in both cases, most of the upsurge in repressive regions were concentrated in Polycomb-repressed regions In addition, we observed a marked drop of all active chromatin states except for weak transcription and distal enhancer activity between the HMEC and vHMEC cells for the hypermethylated group. On the other hand, the hypomethylated group showed multiple notable shifts: From quiescent to Polycomb repression, from weak transcription to strong transcription, and from distal enhancers to genic enhancer (intronic enhancers).
Candidate biomarkers discovery
Nimbl method was used for detection and prioritization of candidate biomarkers with greatest inter-group variability, and lowest intra-group variability [22] . Using this approach, we were able to identify a number of new as well as previously well-known BC biomarkers. Among the genes that showed significant promoter hypermethylation, we identified PAX6 [23, 24] , WT1 [25] , SOX1 [26] , and TP73 [27, 28] , all of them have been previously associated with BC. We also identified a set of previously uncharacterized biomarkers like PCDHGA1, HOXC4, and TBX15. To validate our candidate genes we interrogated our candidate gene list against BC methylome data from the Cancer Genome Atlas Network: http://cancergenome.nih.gov/ as compiled by MethHC [29] web portal. All the genes from our data were also significantly hypermethylated in the TCGA dataset. Table 1 . Performing the pathway enrichment analysis on the breast cancer EUG subnetwork also identified hippo signaling and pathways of extracellular matrix in addition to pathways involved in immune response against viruses Table 2 .
Interestingly, breast cancer subnetwork showed significant enrichment for Epstein-Barr virus infection (FDR <0.001).
Pathway analysis on the EDG network identified Neuroactive ligand-receptor interactions, G-protein signaling, RAP1 signaling, RAS signaling, Potassium channel signaling and many other pathways as summarized in Table 3 . While the smaller EDG breast cancer subnetwork showed significant enrichment for a multitude of pathways including all the pathways that were enriched in the EDG network in addition to many cancer related and immune response pathways. Interestingly, the EDG sub network was also significant for direct p53 effectors. The complete list of enriched pathways for the EDG breast cancer subnetwork is shown in Additional file 3: Table S1 .
Discussion
Reference Human Epigenome Annotations
The recent release of the human reference epigenome data by the Roadmap project ushered in a new era of epigenomics. The current study utilized this new wealth of information to interpret epigenetic data. We successfully mapped hyper and hypo DMPs to chromatin states from normal and premalignant reference breast cells (HMEC and vHMEC respectively). Despite the fact that vHMEC is a premalignant and not a primary tumor cell, we argue that vHMEC is a suitable model for the epigenetic changes that accompany BC tumorigenesis because the vast majority of epigenetic changes tend to occur early during BC tumorigenesis [30] [31] [32] [33] .
Notably, our data revealed a strong Polycomb repression in both hypermethylated and hypomethylated CpG sites. These findings, are in accordance with the emerging evidence that DMPs are enriched for Polycomb repression in primary breast tumors [34] and triple negative BC [35] . Moreover, Various elements of the Polycomb repressive complexes are well known to be overexpressed in BC [36, 37] and are required for stem cell state in mammary tumors [38, 39] . Interestingly, Reyngold et al, found that unlike primary tumors, genes methylated in metastatic lesions seem to lack Polycomb repressive marks [40] .
Network-Based pathway enrichment analysis
Our network-based pathway enrichment results for the EUG network revealed many upregulated pathways that have been previously associated with BC tumorigenesis.
Hippo signaling, which appeared as the top significantly enriched pathway in our results, has recently emerged as an important regulator of BC growth, migration, invasiveness, stemness, as well as drug resistance [41] . Wang et al, demonstrated that overexpression of YAP enhanced BC formation and growth. Hiemer et al, found that both TAZ and YAP -key effectors of the Hippo pathway -are crucial to promote and maintain TGFβ-induced tumorigenic phenotypes in breast cancer cells [42] . In addition, YAP was demonstrated to mediate drug resistance to RAF and MEK targeted cancer therapy [43, 44] . Interestingly, we also reported an upregulated Wnt signaling pathway, which has been linked to BC growth and malignant behavior [45] . Jinhua et al found that Wnt signaling pathway is required for triple-negative breast cancer development [46] .
Recent studies have suggested long lasting reduced Wnt signaling as the mechanism by which early pregnancy protects against BC [47] .
Regarding the EDG network, Neuroactive ligand-receptor interaction, in addition to GPCR, RAS and Rap1 signaling were among the most significantly enriched pathways.
Recent studies have found Neuroactive ligand-receptor interaction related genes to be hypermethylated in colorectal and EBV associated gastric cancers [20, 21] . Elements of RAS signaling like RASSF has been frequently found to be hypermethylated in BC [49] , moreover, Qin et al, has demonstrated that resveratrol is able to demethylate RASSF1 promoter through decreased DNMT1 and DNMT3b in mammary tumors [50, 51] .
Notably, we reported the apparent silencing of multiple pro-tumor pathways in our results like GPCR and RAP1 signaling, the precise significance of this findings remains unclear. In addition, we also noticed the bivalent enrichment of multiple pathways (where different elements of the same pathway are both up and down regulated).
Interpreting such perturbations is tricky, and predicting the net outcome of those perturbations might not be readily obvious given the crosstalk between different pathways.
EBV signature
We previously reported a strong association between EBV and BC in Sudanese patients [52] , we also reported frequent epigenetic silencing of major tumor suppressor genes coupled with low frequency of known tumor associated mutations in the same population [53] . In this study, we have demonstrated genome-wide epigenetic alterations consistent with our original proposition that epigenetic changes are the primary driver of BC tumorigenesis in Sudanese patients.
A myriad of recent studies point toward a common theme in EBV associated cancers characterized by genome-wide epigenetic changes coupled with a paucity of mutations.
EBV infection is now known to play significant role in epithelial cancers like nasopharyngeal and gastric carcinomas mainly through genome-wide epigenetic changes [54] [55] [56] . Li et al observed a unique epiphenotype of EBV associated carcinomas suggesting a predominant role for EBV infection in the ensuing epigenetic dysregulation of those cancers [17] . Another study attributed the genome-wide promoter methylation in EBV driven gastric cancer to the induced expression of DNA methyltransferase-3b (DNMT3b) [57] .
Our data mirrored the overall unique pattern of EBV infection characterized by sweeping epigenetic changes accompanied by low mutation frequency. Furthermore, we also showed that the EUG network was significantly enriched for EBV infection pathway 
Conclusions
In conclusion, our study uncovered interesting epigenetic patterns characterized by increased acquisition of Polycomb repressive marks, as revealed from comparison to human reference epigenome breast cells. We identified many potential BC biomarkers like TP73, and TBX15. We also identified many significantly enriched developmental pathways including Hippo and Wnt signaling pathways. Additionally, our bioinformatics analysis indicated a possible role for EBV infection in BC tumorigenesis.
Materials and Methods
Ethical considerations
Ethical approval for this study was obtained from the Institute of Endemic Diseases, University of Khartoum Ethical Committee. Written informed consent was obtained from all participants; all clinical investigations were conducted according to the principles expressed in the Declaration of Helsinki:
http://www.wma.net/en/30publications/10policies/b3/index.html Samples, DNA extraction, and Illumina Infinium HumanMethylation 450 (HM450) array Genomic DNA was extracted from eight samples of primary breast tumors and eight normal samples from adjacent healthy. All samples were independently reviewed by histopathologists. DNA was extracted from tissues using Promega genomic DNA purification kit [59] following the standard protocol as described by the manufacturer. Nimbl core module identify potential biomarkers by calculating a score based on the inter-group and intra-group variability:
Where beta_valdist is the distance in beta values between non-overlapping groups and mediandiff is the absolute difference of the medians of each group [22] . It then assigns high scores for CpG sites that achieve higher discrimination between groups while maintaining low within-group variability. Nimbl-compare module was also used to extract the final set of CpG sites that were identified by all three methods. Hierarchical clustering analysis was performed using the top 250 differentially methylated sites sorted by F value.
Reference Epigenome Annotations
Bed files of chromatin states for both HMEC and vHMEC cells were obtained from Roadmap web portal: http://egg2.wustl.edu/roadmap/web_portal/, further analysis was performed in GALAXY web-based platform [63] [64] [65] and R statistical software.
Network and Pathway Analysis
Differential methylation analysis produced two lists of differentially methylated genes (hyper and hypo) and their enrichment of differentially methylated sites in their gene regions, i.e., promoter region, gene body, 3UTR, etc. The aggregated gene list was sorted by the count of methylated sites in the promoter area, first exon, and gene body regions. Subsequently all epigenetically upregulated genes (EUG) were combined in a single group, i.e., genes bearing methylation marks that promote gene expressionhypomethylation in the promoter area, and first exon or hypermethylation in the gene body region-in a single group. Then we compiled a second group of epigenetically downregulated genes (EDG), i.e., genes bearing methylation marks that inhibits gene expression, i.e., hypermethylation of the promoter area, and the first exon or hypomethylation of the gene body region. We excluded other gene-based regions that are not well correlated with gene expression from further analysis.
We utilized ReactomeFI [66] , a Cytoscape [67] app to perform network and pathways analysis. Projecting the lists of EDG and EUG groups through the ReactomeFI functional network produced two corresponding networks. To extract breast cancer specific subnetworks from EUG and EDG groups we loaded NCI cancer index from within the ReactomeFI app, and we selected nodes that corresponded to malignant breast cancer.
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